November 30, 2015
Allergy Therapeutics completes patient enrolment in PQBirch204 Phase II study (Allergic rhinitis)
Allergy Therapeutics, a UK-based specialist in allergy vaccines, has completed randomization with 364 patients entered into the PQBirch204 double-blind, placebo-controlled dose selection study for the specific subcutaneous immunotherapy (SCIT), Pollinex Quattro Birch.